1996 Volume 48 Issue 6 Pages 616-622
High-dose chemotherapy followed by peripheral blood stem cell transplantation (PBSCT) has been expected to improve survival for patients with advanced ovarian cancer as well as hematologic malignant diseases. We applied this treatment to a 50-year-old woman with ovarian cancer that had extended to the írchow's lymph nodes. She was introduced to our department after a suboptimal debulking operation. A pathological diagnosis revealed that the tumor consisted of poorly differentiated serous cystadenocarcinoma originated from the left ovary and disseminated to the peritoneal cavity. The stem cells were mobilized into her peripheral blood by using CAP therapy and G-CSF. The number of CFU -GM harvested was 1.16 10c/kg and they were cryopreserved. After the three cycles of CAP treatment, a second look operation was performed. Microscopic metastasis to the omentum could be demonstrated. Even the level of CAl25 in her serum was within the normal limit. High-dose chemotherapy with 900mg/ml of CBDCA and 900mg/m1 of VP-16 was intravenously administered and followed by both PBSCT and G-CSF. No critical complication was observed except for the necessity of a platelet transfusion. Sustained hemopoietic recovery could be observed two weeks after PBSCT. These findings suggest that high-dose chemotherapy, followed by PBSCT might be useful in the treatment of advanced ovarian cancer. [Adv Obstet Gynecol 48 (6); 616-622, 1996 (H8.11)]
